The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to optimize an accurate and efficient early stage, point of care cancer diagnostic for commercialization and market entry. In 2020, the total cost of cancer care was nearly $210 billion dollars and current cancer diagnostics only allow for diagnosis during late stage disease, resulting in a large economic burden to patients, families, and healthcare providers. Commercialization of the company’s project allows for accurate early-stage cancer detection, enabling healthcare providers to give patients the most appropriate treatment to increase the chances of survival at a lower overall cost. The company’s project will also help increase the cancer diagnostics market size, adding to, for example, the cervical cancer diagnostic market, which was 4.5B USD in 2022, and is expected to increase with a projected compound annual growth rate of 5.7% by 2030. The company’s beachhead market includes dentists, gastroenterologists, and gynecologists. Further, the company has developed a strong partnership with Delta Dental and built relationships with researchers at the University of Miami, University of North Carolina Chapel Hill, and New York University Langone to expand the project to other indications and promote collaboration between academia and industry. This Small Business Technology Transfer (STTR) Phase II project will advance the company’s project as an artificial intell